null

null

null

null

null

null

null

null

null

null

null

null

null

null

1.54x Total Debt / Equity (Elevated leverage)

A 200bps rate increase adds ~$120M annual interest expense given ~$16B gross debt; ~60% fixed-rate mix limits near-term floating exposure but refinancing risk is elevated

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Wuhan/China for renal dialysis membranes and components; Taiwan/Southeast Asia for semiconductor chips used in infusion pumps

EUR (~25% of intl revenue), CNY (~10%), BRL (~5%); EUR weakness vs USD directly pressures reported margins; BRL historically volatile, CNY managed but devaluation risk real post-2024

Top three international markets: Europe (EUR), China (CNY), Brazil (BRL); combined FX translation risk represents ~$200-300M annual revenue headwind in strong-dollar environments

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs; however, specialized membrane and resin suppliers for renal therapies have limited substitutes, creating moderate non-substitutable dependency

Medical device and hospital supply manufacturer; cloud dependency is operational/ERP (SAP/Oracle hosted), not revenue-critical; 30-day cloud termination would disrupt logistics, not product delivery

Secondary cloud use for R&D data analytics and connected device telemetry (Hillrom integration); disruption would delay product development cycles by 3-6 months, not halt revenue

Low API coupling risk; Baxter's revenue model is hardware/consumable-based; digital connectivity platforms (Welch Allyn, ConnectedCare) have moderate but not critical API dependencies

Fails Howey Test; Baxter sells physical medical products and services, not investment contracts; no expectation-of-profits-from-others structure; Howey risk score: negligible

Very High

Moderate GDPR exposure via connected hospital devices in EU (patient vitals data); CCPA exposure limited; Hillrom acquisition increased patient data handling obligations materially

Moderate; hospital group purchasing organization (GPO) contracts and bundled pricing in IV solutions and infusion systems have drawn historical DOJ scrutiny; no active investigations reported

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~60-65% recurring (multi-year hospital supply contracts, renal therapy consumables, service agreements); ~35-40% transactional (capital equipment sales, one-time device purchases)

Razor-and-blade model: capital equipment (pumps, monitors) placed at low margin, recurring consumables (IV sets, dialysate, software subscriptions) generate 60%+ of revenue at higher margins

Cost-plus with GPO contract constraints; limited spot pricing flexibility; Baxter cannot unilaterally reprice IV solutions or dialysis supplies mid-contract; inflation pass-through lag of 12-18 months

Moderate (6/10); essential products limit demand destruction but GPO contracts cap upside; generic competition in IV solutions and commodity consumables constrains premium pricing

30.1% Gross Margin (Moderate (20-40%))

Low free-rider risk; hospital formulary and device standardization creates 3-5 year switching friction; churn is contract-cycle driven, not behavioral; annual churn estimated below 5%

Revenue growth is headcount-sublinear for consumables (manufacturing scale), but headcount-linear for services and clinical support; doubling revenue requires ~40-50% headcount increase

Marginal cost of growth is moderate; incremental consumable revenue has ~55-60% gross margin; new capital equipment sales require SG&A and clinical specialist investment, diluting incrementals

Not applicable; Baxter does not operate a franchise model; distribution is direct and through authorized distributors under regulated medical device compliance frameworks

At 10x scale, GPO negotiation leverage flips against Baxter; hospital consolidation reduces buyer count, increasing concentration risk; CAC rises as remaining unconverted accounts are harder targets

Weak network effects; connected care platform (Hillrom) has mild data-network benefits (benchmarking analytics) but core IV/renal business has no network effects; durability rating: low

-2.5% Return on Assets (Negative equity)

Tier 1 recession-resistant; renal dialysis, IV therapy, and ICU equipment are non-deferrable; hospital capex cuts affect capital equipment but consumables remain stable through economic cycles

Acute care hospitals and health systems (>70% of revenue); top 10 hospital systems/IDNs likely represent 20-25% of US revenue, indicating moderate concentration risk

Renal dialysis centers (DaVita, Fresenius) represent significant secondary segment; DaVita alone may represent 5-8% of global revenue, creating meaningful single-customer concentration

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is split: ~40% maintenance of legacy IV and renal manufacturing plants, ~35% Hillrom integration/digital infrastructure, ~25% growth capex; transition underway but legacy drag persists through 2026

0000010456

BAX